Vestmark Advisory Solutions Inc. Invests $5.04 Million in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Vestmark Advisory Solutions Inc. purchased a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 2,984,617 shares of the company’s stock, valued at approximately $5,044,000. Vestmark Advisory Solutions Inc. owned 0.14% of Ginkgo Bioworks as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of DNA. Prime Capital Investment Advisors LLC acquired a new position in shares of Ginkgo Bioworks in the 4th quarter worth approximately $37,000. Stratos Wealth Partners LTD. bought a new position in shares of Ginkgo Bioworks in the 3rd quarter worth about $43,000. Smith Salley & Associates boosted its position in shares of Ginkgo Bioworks by 100.0% during the 4th quarter. Smith Salley & Associates now owns 24,000 shares of the company’s stock valued at $41,000 after purchasing an additional 12,000 shares in the last quarter. Headlands Technologies LLC bought a new stake in Ginkgo Bioworks in the third quarter worth approximately $53,000. Finally, QCM Cayman Ltd. lifted its stake in Ginkgo Bioworks by 56.5% in the third quarter. QCM Cayman Ltd. now owns 32,446 shares of the company’s stock valued at $59,000 after buying an additional 11,716 shares during the period. Institutional investors own 78.63% of the company’s stock.

Ginkgo Bioworks Stock Up 10.9 %

Shares of NYSE DNA traded up $0.09 during mid-day trading on Friday, reaching $0.96. 54,556,311 shares of the company’s stock traded hands, compared to its average volume of 45,144,840. The business has a 50-day simple moving average of $1.08 and a 200 day simple moving average of $1.32. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $0.74 and a 1-year high of $2.55.

Ginkgo Bioworks (NYSE:DNA) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Ginkgo Bioworks had a negative net margin of 355.08% and a negative return on equity of 48.23%. The company had revenue of $34.76 million for the quarter, compared to analyst estimates of $40.37 million. During the same quarter last year, the firm posted ($0.04) EPS. Ginkgo Bioworks’s revenue for the quarter was down 64.6% on a year-over-year basis. On average, equities research analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -0.32 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on DNA shares. The Goldman Sachs Group lowered their price objective on shares of Ginkgo Bioworks from $1.25 to $1.10 and set a “sell” rating for the company in a research note on Monday, January 22nd. TD Cowen decreased their target price on Ginkgo Bioworks from $7.00 to $3.00 and set an “outperform” rating for the company in a research report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, Ginkgo Bioworks has an average rating of “Hold” and an average price target of $2.20.

Insider Buying and Selling at Ginkgo Bioworks

In other news, insider Mark E. Dmytruk sold 51,169 shares of the stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $1.05, for a total value of $53,727.45. Following the completion of the sale, the insider now owns 865,079 shares in the company, valued at $908,332.95. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 15.05% of the company’s stock.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.